Potential cancer risk with omalizumab? A disproportionality analysis of the WHO's VigiBase pharmacovigilance database-Reference-Cited by-同舟云学术

Potential cancer risk with omalizumab? A disproportionality analysis of the WHO's VigiBase pharmacovigilance database

Published:2021-07-22 Issue:10 Volume:76 Page:3209-3211
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Mota Diogo¹,Rama Tiago Azenha¹²^ORCID,Severo Milton³,Moreira André¹²³^ORCID

Affiliation:

1. Serviço de Imunoalergologia Centro Hospitalar Universitário de São João Porto Portugal

2. Serviço de Imunologia Básica e Clínica Faculdade de Medicina da Universidade do Porto Portugal

3. EPIUnit Instituto de Saúde Pública e Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (ITR) Universidade do Porto Porto Portugal

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.15008

Reference6 articles.

1. AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer—a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI)

2. Omalizumab and the risk of malignancy: Results from a pooled analysis

3. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab

4. Case–non-case studies: Principle, methods, bias and interpretation

5. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Safety Profile of Biologic Drugs for Severe Uncontrolled Asthma: A Descriptive Analysis from the Spanish Pharmacovigilance Database;Journal of Clinical Medicine;2024-07-18

2. The Burden of Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease: Interplay Between Quality of Life and Economic Implications;The Journal of Allergy and Clinical Immunology: In Practice;2024-07

3. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database;BioDrugs;2024-03-15

4. Does omalizumab increase the risk of malignancy? A retrospective case-control study in a single tertiary hospital;Asia Pacific Allergy;2024-03

5. Real-Life Data on the Use of Omalizumab in Patients with Severe Asthma and Chronic Urticaria and Mepolizumab in Patients with Severe Asthma: A Retrospective Study;OSMANGAZİ JOURNAL OF MEDICINE;2023-09-26